Q-omics provides the consensus-scored RAB27B profile across patient tissues and cancer cell-line models. RAB27B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RAB27B is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, RAB27B protein abundance shows 30,316 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight LUAD, BLCA, and BRCA as cancer lineages where RAB27B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB27B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB27B survival associations across molecular data types. RAB27B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB27B RNA expression–survival associations across cancer types. High RAB27B expression shows unfavorable associations in LUAD, KIRP, PAAD, UVM and LAML, but favorable associations in COAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for RAB27B RNA expression.
This table summarizes RAB27B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 12. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB27B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB27B shows higher tumor expression in BLCA, THCA, KIRP, BRCA, KICH and KIRC. The BLCA box plot shows higher RAB27B RNA expression in tumor versus normal tissue (log2 FC = +1.578, t-test p = .024).
This table shows molecular features associated with RAB27B in patient tissues and cancer cell lines. In patient samples, RAB27B shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB27B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
